Palvella Therapeutics (PVLA) Revenue (2014 - 2024)

Palvella Therapeutics (PVLA) has 11 years of Revenue data on file, last reported at $53000.0 in Q1 2024.

• On a quarterly basis, Revenue fell 97.36% year-over-year to $53000.0 in Q1 2024; TTM through Sep 2024 was -$2.7 million, a 106.58% decrease from a year earlier, with the FY2023 full-year figure at $38.7 million, up 8840.18% from the prior year.
• Revenue for Q1 2024 stood at $53000.0, up from -$2.8 million in the prior quarter.
• Over the last five years, Revenue for PVLA reached as high as $20.1 million in Q2 2023 and fell as low as -$3.5 million in Q4 2020.
• Historically, Revenue has averaged $5.9 million across 5 years, with a median of $2.6 million in 2020.
• On a YoY basis, Revenue climbed as much as 8619.57% in 2023 and fell as far as 2143.8% in 2023.
• Year by year, Revenue stood at -$3.5 million in 2020, then soared by 338.84% to $8.4 million in 2021, then plunged by 98.38% to $137000.0 in 2022, then slumped by 2143.8% to -$2.8 million in 2023, then soared by 101.89% to $53000.0 in 2024.
• Per Business Quant data, the three most recent Revenue figures were $53000.0 in Q1 2024, -$2.8 million in Q4 2023, and $19.5 million in Q3 2023.